



**Consumer Healthcare**  
184 Liberty Corner Road  
Suite 200                    Warren, NJ  
07059

[www.gsk.com](http://www.gsk.com)

Jan 18<sup>th</sup> 2018

*Attention: Application Examiner*

*RE: Request for Confidentiality*

*Applicant:*

GSK Consume Healthcare  
184 Liberty Corner Rd  
Warren  
NJ 07059, U.S.A

*FCC ID: 2ANMMMQB1*

To Whom It May Concern:

## Long-term Confidentiality

Request is hereby submitted by **GSK Consumer Healthcare** to withhold permanently from public review certain portions of the application for equipment certification for the referenced FCC identifiers. This request for confidentiality is made pursuant to 47 CFR 0.457(d) and 0.459 of the FCC Rules. In particular, the following sections of the application are to be kept permanently confidential:

- Schematics (attachment *GLX00039159-100-SF\_Rev.C02*)
  - Detailed Block Diagrams (attachment *Block\_Schematic\_GSK\_Antenna*)
  - Detailed Operational/Functional Description

## Short-term Confidentiality

Request is hereby submitted by **GSK Consumer Healthcare** to withhold from public review for a period of 180 days from the date of the Grant of Equipment Authorization and prior to marketing, certain portions of the application for equipment certification for the referenced FCC identifiers. This request for confidentiality is made pursuant to 47 CFR 0.457(d) and 0.459 of the FCC Rules. In particular, the following sections of the application are to be kept confidential for a period of 180 days from the date of Authorization:

- External photos
  - Test set-up Photos
  - Internal photos
  - User's Manual (attachment *106220XA\_NRO\_MYQ\_WD\_Band\_PCard\_DL-1*;  
*106221XA\_NRO\_MyQuit\_WD\_Insert\_DL-2*;  
*MyQuit App -Wristband related screens*)

Rationale for request for confidentiality:

**GSK Consumer Healthcare** has invested considerable time and materials in research and development to produce the referenced product.


Disclosure of the permanently confidential portions of this application to competitors would provide unjustified benefits to our competitors.

Disclosure of the short-term confidential portions of this application during the period of importation and/or distribution would reveal key aspects to competitors and diminish the value of our investment in research and development.

The applicant understands that pursuant to Section 0.457 of the Rules, disclosure of this application and all accompanying documentation will not be made before the date of the Grant for this application.

Sincerely,

Guliz Guler  
Senior Regulatory Affairs Manager  
GSK Consumer Healthcare

A handwritten signature in blue ink, appearing to read "Guliz Guler".